EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

First- Versus Second- or Subsequent-Line Use of Cyclin-Dependent Kinase 4/6 Inhibitors for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic or Recurrent Breast Cancer: A Multicenter, Retrospective Cohort Study

Shoko Yao iD, Shigeru Imoto iD, Ai Tsuchiya, Hirotsugu Isaka, Hirohito Seki iD, Sota Asaga iD, Shigehiro Yokoi iD, Kenji Koneri iD, Hiroyuki Maeda iD, Takanori Goi iD

Medicina · 2026

DOI: 10.3390/medicina62040661 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Medicina, 2026. Verfasst von Shoko Yao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal and Breast Surgery, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy are recommended as first- or second-line treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or recurrent breast cancer. However, in clinical practice, initiation timing varies according to patient characteristics, prior treatments, and the choice of the physician. Thus, the optimal timing of combination treatment remains unclear. Materials and Methods: In this multicenter retrospective cohort study, we reviewed 66 female patients who received CDK4/6i (palbociclib or abemaciclib) between March 2018 and November 2019. Patients were categorized into the first-line treatment (group A) (n = 21) and second- or subsequent-line treatment (group B) (n = 45) groups. In the latter group, endocrine therapy and/or chemotherapy had been administered previously. Duration of treatment with CDK4/6i (DOT), overall survival (OS), treatment duration of other regimens, and reasons for treatment discontinuation after CDK4/6i treatment were compared between groups.

Results

The median DOT was significantly longer in group A than in group B (23 months (95% CI, 8–43) vs. 7 months (95% CI, 3–15); p = 0.015, at log-rank test). OS showed no significant difference between the two groups (p = 0.69, at log-rank test).

Conclusions

In patients with HR-positive, HER2-negative advanced or recurrent breast cancer, first-line use of CDK4/6 inhibitors was associated with a significantly longer duration of treatment compared with second- or subsequent-line use. However, no significant difference in OS was observed between patients receiving CDK4/6 inhibitors as first-line or second- or subsequent-line therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsHumansFemaleRetrospective StudiesErb-b2 Receptor Tyrosine KinasesBenzimidazolesPiperazinesAminopyridinesMiddle AgedPyridinesAgedNeoplasm Recurrence, LocalCohort StudiesAdult

Stichwörter der Autor:innen

CDK4/6 inhibitorsHER2-negativeabemaciclibbreast cancerhormone receptor-positivepalbociclibtreatment sequencing

Substanzen

Erb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6BenzimidazolesabemaciclibPiperazinesAminopyridinesPyridinesERBB2 protein, humanpalbociclib

Autor:innen und Institutionen

  • Department of Gastrointestinal and Breast Surgery, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan.
  • Department of Breast Surgery, School of Medicine, Kyorin University, 6-20-2 Shinkawa, Mitaka-shi, Tokyo 181-8611, Japan.
  • Department of Surgery, Keiyu Hospital, 3-7-3 Minatomirai, Nishi-ku, Yokohama City 220-8521, Kanagawa, Japan.

ORCID-Profile: Shoko Yao, Shigeru Imoto, Hirohito Seki, Sota Asaga, Shigehiro Yokoi, Kenji Koneri, Hiroyuki Maeda, Takanori Goi

Zitieren

APA

Yao, S., Imoto, S., Tsuchiya, A., Isaka, H., Seki, H., Asaga, S., Yokoi, S., Koneri, K., Maeda, H., & Goi, T. (2026). First- Versus Second- or Subsequent-Line Use of Cyclin-Dependent Kinase 4/6 Inhibitors for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic or Recurrent Breast Cancer: A Multicenter, Retrospective Cohort Study. Medicina. https://doi.org/10.3390/medicina62040661

Vancouver

Yao S, Imoto S, Tsuchiya A, Isaka H, Seki H, Asaga S, et al. First- Versus Second- or Subsequent-Line Use of Cyclin-Dependent Kinase 4/6 Inhibitors for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic or Recurrent Breast Cancer: A Multicenter, Retrospective Cohort Study. Medicina. 2026. doi:10.3390/medicina62040661

BibTeX
@article{Yao2026,
  author = {Yao, Shoko and Imoto, Shigeru and Tsuchiya, Ai and Isaka, Hirotsugu and Seki, Hirohito and Asaga, Sota and Yokoi, Shigehiro and Koneri, Kenji and Maeda, Hiroyuki and Goi, Takanori},
  title = {First- Versus Second- or Subsequent-Line Use of Cyclin-Dependent Kinase 4/6 Inhibitors for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic or Recurrent Breast Cancer: A Multicenter, Retrospective Cohort Study},
  journal = {Medicina},
  year = {2026},
  doi = {10.3390/medicina62040661}
}
Kostenlos starten →